Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

135 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Staphylococcus aureus induces drug resistance in cancer T cells in Sézary syndrome.
Vadivel CK, Willerslev-Olsen A, Namini MRJ, Zeng Z, Yan L, Danielsen M, Gluud M, Pallesen EMH, Wojewoda K, Osmancevic A, Hedebo S, Chang YT, Lindahl LM, Koralov SB, Geskin LJ, Bates SE, Iversen L, Litman T, Bech R, Wobser M, Guenova E, Kamstrup MR, Ødum N, Buus TB. Vadivel CK, et al. Among authors: geskin lj. Blood. 2024 Apr 11;143(15):1496-1512. doi: 10.1182/blood.2023021671. Blood. 2024. PMID: 38170178 Free PMC article.
Romidepsin and Afatinib Abrogate Jak-Signal Transducer and Activator of Transcription Signaling and Elicit Synergistic Antitumor Effects in Cutaneous T-Cell Lymphoma.
Shih BB, Ma C, Cortes JR, Reglero C, Miller H, Quinn SA, Albero R, Laurent AP, Mackey A, Ferrando AA, Geskin L, Palomero T. Shih BB, et al. J Invest Dermatol. 2024 Jan 14:S0022-202X(23)03210-4. doi: 10.1016/j.jid.2023.12.010. Online ahead of print. J Invest Dermatol. 2024. PMID: 38219917 Free article.
Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial.
Prince HM, Kim YH, Horwitz SM, Dummer R, Scarisbrick J, Quaglino P, Zinzani PL, Wolter P, Sanches JA, Ortiz-Romero PL, Akilov OE, Geskin L, Trotman J, Taylor K, Dalle S, Weichenthal M, Walewski J, Fisher D, Dréno B, Stadler R, Feldman T, Kuzel TM, Wang Y, Palanca-Wessels MC, Zagadailov E, Trepicchio WL, Zhang W, Lin HM, Liu Y, Huebner D, Little M, Whittaker S, Duvic M; ALCANZA study group. Prince HM, et al. Lancet. 2017 Aug 5;390(10094):555-566. doi: 10.1016/S0140-6736(17)31266-7. Epub 2017 Jun 7. Lancet. 2017. PMID: 28600132
Evaluating the efficacy of combination and single-agent immunotherapies in real-world patterns of disease progression and survival of metastatic melanoma patients.
Ko B, Tao K, Brennan L, Rakhade S, Chan CX, Moone JY, Zhu R, Sher A, Wang S, Bracero Y, Fullerton B, McLellan B, Geskin LJ, Saenger YM. Ko B, et al. Among authors: geskin lj. Melanoma Res. 2024 Apr 1;34(2):134-141. doi: 10.1097/CMR.0000000000000945. Epub 2024 Jan 4. Melanoma Res. 2024. PMID: 38181115 Free PMC article.
Paediatric onset lymphomatoid papulosis: results of a multicentre retrospective cohort study, on behalf of the EORTC Cutaneous Lymphoma Tumours Group (CLTG).
Blanchard M, Morren MA, Busschots AM, Hauben E, Alberti-Violetti S, Berti E, Avallone G, Tavoletti G, Panzone M, Quaglino P, Colonna C, Melchers RC, Vermeer MH, Gniadecki R, Mitteldorf C, Gosmann J, Stadler R, Jonak C, Oren-Shabtai M, Hodak E, Friedland R, Gordon E, Geskin LJ, Scarisbrick JJ, Mayo Martínez F, Noguera Morel L, Pehr K, Amarov B, Faouzi M, Nicolay JP, Kempf W, Blanchard G, Guenova E. Blanchard M, et al. Among authors: geskin lj. Br J Dermatol. 2024 Apr 10:ljae150. doi: 10.1093/bjd/ljae150. Online ahead of print. Br J Dermatol. 2024. PMID: 38595050
Gammopathic dermopathy: characterization of cutaneous MGUS.
Gordon ER, Chen C, Trager MH, Adeuyan O, Lapolla BA, Fahmy LM, Schreidah CM, Wetter DA, Geskin LJ. Gordon ER, et al. Among authors: geskin lj. Leuk Lymphoma. 2024 Apr 6:1-8. doi: 10.1080/10428194.2024.2336046. Online ahead of print. Leuk Lymphoma. 2024. PMID: 38581379
135 results